Asim Ayesha, Jastrzębski Michał K, Kaczor Agnieszka A
Department of Synthesis and Chemical Technology of Pharmaceutical Substances with Computer Modeling Laboratory, Faculty of Pharmacy, Medical University of Lublin, 4A Chodźki St., PL-20093 Lublin, Poland.
School of Pharmacy, University of Eastern Finland, Yliopistonranta 1, P.O. Box 1627, FI-70211 Kuopio, Finland.
Molecules. 2025 Jul 15;30(14):2975. doi: 10.3390/molecules30142975.
Alzheimer's disease (AD) is a multi-factorial neurodegenerative disease with a complex pathomechanism that can be best treated with multi-target medications. Among the possible molecular targets involved in AD, acetylcholinesterase (AChE) and monoamine oxidase B (MAO-B) are well recognized because they control the neurotransmitters responsible for memory processes. This review discusses the current understanding of AD pathology, recent advances in AD treatment, and recent reports in the field of dual AChE/MAO-B inhibitors for treating AD. We provide a classification of dual inhibitors based on their chemical structure and describe active compounds belonging to, i.a., chalcones, coumarins, chromones, imines, and hydrazones. Special emphasis is given to the computer-aided strategies of dual inhibitors design, their structure-activity relationships, and their interactions with the molecular targets at the molecular level.
阿尔茨海默病(AD)是一种多因素神经退行性疾病,其病理机制复杂,最佳治疗方法是使用多靶点药物。在AD涉及的可能分子靶点中,乙酰胆碱酯酶(AChE)和单胺氧化酶B(MAO-B)广为人知,因为它们控制着负责记忆过程的神经递质。本综述讨论了目前对AD病理学的理解、AD治疗的最新进展以及双AChE/MAO-B抑制剂治疗AD领域的最新报告。我们根据其化学结构对双抑制剂进行了分类,并描述了属于查耳酮、香豆素、色酮、亚胺和腙等类别的活性化合物。特别强调了双抑制剂设计的计算机辅助策略、它们的构效关系以及它们在分子水平上与分子靶点的相互作用。